Clinical efficacy of hepatic arterial infusion chemotherapy combined with atelizumab plus bevacizumab on first line treatment of advanced hepatocellular carcinoma
10.3760/cma.j.cn115610-20220909-00505
- VernacularTitle:肝动脉灌注化疗联合阿替利珠单克隆抗体与贝伐珠单克隆抗体一线治疗晚期肝细胞癌的临床疗效
- Author:
Linsen YE
1
;
Haoyuan YU
;
Siqi LI
;
Zhenyu YU
;
Genshu WANG
;
Yang LI
Author Information
1. 中山大学附属第三医院肝脏外科暨肝移植中心 中山大学器官移植研究所 广东省器官移植研究中心 广东省移植医学工程实验室，广州 510515
- Keywords:
Liver neoplasms;
Immunotherapy;
Target therapy;
Combined therapy;
Conversion therapy
- From:
Chinese Journal of Digestive Surgery
2022;21(S1):5-9
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of advanced hepatocellular carcinoma (HCC) is limited and the prognosis is poor, which seriously endangers the public health. Results of clinical trials have confirmed the validity of atelizumab plus bevacizumab in patients with advanced HCC. The authors introduce the clinical experience of a patient with stage Ⅲa HCC undergoing local therapy of hepatic artery chemoembolization, and combined with atelizumab plus bevacizumab. The results show that patient with successfully transformational therapy, and receiving surgical resection with a good clinical effect.
